Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Down 19.2% in January

Dominari Holdings Inc. (NASDAQ:DOMH) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 574,812 shares, a decrease of 19.2% from the December 31st total of 711,007 shares. Based on an average daily trading volume, of 262,346 shares, the days-to-cover ratio is presently 2.2 days. Currently, 5.1% of the company’s stock are short sold. Currently, 5.1% of the company’s stock are short sold. Based on an average daily trading volume, of 262,346 shares, the days-to-cover ratio is presently 2.2 days.

Dominari Stock Performance

Shares of NASDAQ DOMH traded down $0.16 during mid-day trading on Wednesday, reaching $3.80. 71,254 shares of the company traded hands, compared to its average volume of 190,472. The company’s fifty day moving average is $4.36 and its two-hundred day moving average is $5.29. Dominari has a fifty-two week low of $2.55 and a fifty-two week high of $13.58. The stock has a market cap of $61.64 million, a PE ratio of 0.68 and a beta of 0.74.

Dominari Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Monday, January 5th were issued a dividend of $0.445 per share. The ex-dividend date of this dividend was Monday, January 5th.

Insider Activity

In other news, COO Christopher Franklin Devall sold 45,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $3.85, for a total transaction of $173,250.00. Following the transaction, the chief operating officer directly owned 145,702 shares in the company, valued at $560,952.70. The trade was a 23.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last three months, insiders have sold 225,000 shares of company stock worth $876,850. Company insiders own 29.92% of the company’s stock.

Institutional Investors Weigh In On Dominari

Several hedge funds have recently modified their holdings of DOMH. PFG Investments LLC bought a new stake in Dominari in the 4th quarter valued at $53,000. Connective Capital Management LLC lifted its position in shares of Dominari by 26.2% in the 3rd quarter. Connective Capital Management LLC now owns 335,273 shares of the company’s stock worth $2,377,000 after acquiring an additional 69,545 shares during the period. Millennium Management LLC acquired a new stake in shares of Dominari during the 3rd quarter worth approximately $213,000. Two Sigma Investments LP acquired a new stake in shares of Dominari during the 3rd quarter worth approximately $771,000. Finally, Vanguard Group Inc. increased its position in shares of Dominari by 8.0% during the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after purchasing an additional 25,694 shares during the period. 42.48% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DOMH has been the topic of a number of recent research reports. Weiss Ratings downgraded Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. Wall Street Zen downgraded Dominari from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Dominari has a consensus rating of “Sell”.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.